GlobeNewswire BiotechnologyQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 04:15:00·⟳ 抓取 04:16:19·⚡ 决策 08-27 04:17:29 +1m10s·61.9 天前
First Tracks Biotherapeutics宣布管理层将参加9月多场投资者会议
这是一则例行的投资者会议参加公告，不含任何新增基本面事实（无临床数据、无监管决定、无合作/订单、无指引变化），对股价无方向性影响，不构成可交易催化
📄 原文GlobeNewswire Biotechnology↗ 原文
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotec…
不做 First Tracks Biotherapeutics（TRAX.US）
例行投资者会议参加公告，不含任何新增临床数据、监管进展、合作或财务信息，无方向性催化，无可交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
First Tracks Biotherapeutics宣布管理层参加9月三场投资者会议（Wells Fargo、Citi、Morgan Stanley）。这是临床阶段生物科技公司的标准IR活动，不包含任何新增临床数据、监管进展、商业合作或财务信息。会议本身要到9月9-16日才举行，届时若有数据披露才可能构成催化。本次公告无增量信息，方向中性，不构成交易机会。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无先例需要，因为事件本身不构成催化
方向:不适用——会议参加公告无方向性
涨幅量级:不适用
形态:不适用
工具调用 · 历史记录,结果未知(2 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 1,713 字
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:
21
st
Annual Wells Fargo Healthcare Conference, Boston
Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT
Citi's 2026 Biopharma Back to School Conference, New York City
Format – One-on-one investor meetings
Date and Time – Thursday, Sept. 10, 2026
Morgan Stanley 24th Annual Global Healthcare Conference, New York City
Format – One-on-one investor meetings
Date and Time – Wednesday, Sept. 16, 2026
A live webcast of the fireside chat will be available on the investor section of the First Tracks website at
https://ir.firsttracksbio.com/news-events/events
. A replay of the webcast will be available for at least 30 days following the event.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit
www.FirstTracksBio.com
or follow us on
LinkedIn
.
Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com
21
st
Annual Wells Fargo Healthcare Conference, Boston
Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Sept. 9, 2026 at 9:30am ET / 6:30am PT
Citi's 2026 Biopharma Back to School Conference, New York City
Format – One-on-one investor meetings
Date and Time – Thursday, Sept. 10, 2026
Morgan Stanley 24th Annual Global Healthcare Conference, New York City
Format – One-on-one investor meetings
Date and Time – Wednesday, Sept. 16, 2026
A live webcast of the fireside chat will be available on the investor section of the First Tracks website at
https://ir.firsttracksbio.com/news-events/events
. A replay of the webcast will be available for at least 30 days following the event.
About First Tracks Biotherapeutics
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit
www.FirstTracksBio.com
or follow us on
.
Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。